Your partner in oncology Home About us Consulting Preclinical Techniques Clinical Publications Publications 2012-2015 Publications 2000-2011 Events Contact Consulting OTD provides independent consulting services in oncology early drug development. Preclinical We offer integrated drug discovery services and routinely conduct contract preclinical research. Clinical The OTD team has collective experience managing over 50 Phase I-II oncology clinical trials. oncology therapeUtic development A CRO focused solely on oncology, specialized in the early development of single agent and combination anticancer regimens. Ensure rapid and efficient development of promising new cancer treatments Offer preclinical and clinical consulting for VC groups or mid-size biotech companies Optimize, launch and execute your clinical development plan Support companies by providing strong medical input and oncology-experienced staff Are a key partner working with small and mid-size companies Can design preclinical models to guide clinical development Perform clinical Phase I/II study design and implementation Our goal is to support our partners to establish a clinical development plan to generate data in a timely, efficient and cost-effective manner. Publication BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells. Coudé MM, Braun T, Berrou J, Dupont M, Bertrand S, Masse A, Raffoux E, Itzykson R, Delord M, Riveiro ME, Herait P, Baruchel A, Dombret H, Gardin C. Oncotarget. 2015 May 14 Go to Publication Events AACR Annual Meeting 2015. April 18-22, 2015. Philadelphia, Pennsylvania. Go to Events Contact OTD - Oncology Therapeutic Development 100 rue Martre 92110 Clichy - FRANCE Tel: +33 1 47 15 01 01 Fax: +33 1 45 19 06 59 Contact Us Contact - Sitemap Réalisé par Clikeo